These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29318029)

  • 1. Thrombin generation correlates with disease duration in multiple sclerosis (MS): Novel insights into the MS-associated prothrombotic state.
    Parsons ME; O'Connell K; Allen S; Egan K; Szklanna PB; McGuigan C; Ní Áinle F; Maguire PB
    Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317747624. PubMed ID: 29318029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance spectroscopic findings of chronic lesions in two subtypes of multiple sclerosis: primary progressive versus relapsing remitting.
    Rahimian N; Saligheh Rad H; Firouznia K; Ebrahimzadeh SA; Meysamie A; Vafaiean H; Harirchian MH
    Iran J Radiol; 2013 Sep; 10(3):128-32. PubMed ID: 24348597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
    PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing-Remitting and Primary Progressive Multiple Sclerosis.
    Cao Y; Diao W; Tian F; Zhang F; He L; Long X; Zhou F; Jia Z
    Neuropsychol Rev; 2021 Dec; 31(4):703-720. PubMed ID: 33582965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
    Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
    J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
    [No Abstract]   [Full Text] [Related]  

  • 14. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography.
    Adesanya MA; Maraveyas A; Madden LA
    Thromb Res; 2016 Apr; 140 Suppl 1():S186. PubMed ID: 27161715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
    Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
    Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olfactory dysfunction in patients with primary progressive MS.
    Schmidt FA; Maas MB; Geran R; Schmidt C; Kunte H; Ruprecht K; Paul F; Göktas Ö; Harms L
    Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e369. PubMed ID: 28638852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
    Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis.
    Mutukula N; Man Z; Takahashi Y; Iniesta Martinez F; Morales M; Carreon-Guarnizo E; Hernandez Clares R; Garcia-Bernal D; Martinez Martinez L; Lajara J; Nuñez Delicado E; Meca Lallana JE; Izpisua Belmonte JC
    Stem Cell Res; 2021 May; 53():102319. PubMed ID: 33894548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Reuling IE; Polman CH
    Neurology; 2004 Jul; 63(2):335-9. PubMed ID: 15277630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.